Keeps BioPharma

Keeps BioPharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Keeps BioPharma (256940.KQ) as of Oct 29, 2026 is 1.57 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 7.64 B KRW — a change of -79.38% (lower).

EBITDA

1.57 BKRW

YoY

-79.38%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Keeps BioPharma is 2025 1.57 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Keeps BioPharma was 2024 7.64 B KRW. It decreases by -79.38% lower compared to the previous year.

The Keeps BioPharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
4.47 B KRW
Jan 1, 2018
7.83 B KRW
Jan 1, 2019
-678.01 M KRW
Jan 1, 2020
-123.07 M KRW
Jan 1, 2021
-12.05 B KRW
Jan 1, 2022
-7.30 B KRW
Jan 1, 2024
7.64 B KRW
Jan 1, 2025
1.57 B KRW
The Keeps BioPharma EBITDA history
YEAREBITDAYoY
1.57 BKRW-79.38%
7.64 BKRW-204.65%
-7.30 BKRW-39.42%
-12.05 BKRW+9,687.81%
-123.07 MKRW-81.85%
-678.01 MKRW-108.66%
7.83 BKRW+75.17%
4.47 BKRW+28.99%
3.46 BKRW-1,094.60%
-348.32 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Keeps BioPharma Stock analysis

What does Keeps BioPharma do? Keeps BioPharma Inc, operating under the KPS Corp brand, is headquartered in Hwaseong, South Korea. Listed on the stock exchange in December 2016, the company engages in the manufacture and sale of specialized machinery for flat panel displays. With a workforce of 49 employees, its product portfolio includes mask stretchers, support mask stretchers, total pitch inspection systems, open mask tension welders, lamination and de-lamination systems, inkjet printers, diffusion systems, and panel inspection systems. The firm operates within the Information Technology sector, specifically in the Semiconductors industry, providing essential equipment for display manufacturing processes. Keeps BioPharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Keeps BioPharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Keeps BioPharma is 1.57 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Keeps BioPharma changed from 7.64 B KRW to 1.57 B KRW, representing a -79.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Keeps BioPharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Keeps BioPharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Keeps BioPharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Keeps BioPharma